Article Text

Download PDFPDF
Psoriatic arthritis: update on pathophysiology, assessment and management
  1. Philip J Mease
  1. Division of Rheumatology Research, Swedish Medical Center; Seattle, Washington, USAUniversity of Washington School of Medicine, Seattle, Washington, USA
  1. Correspondence to Dr Philip J Mease, Seattle Rheumatology Associates, 1101 Madison St Ste 1000, Seattle, WA 98104, USA; pmease{at}


Psoriatic arthritis (PsA) is classified as a spondyloarthropathy and characterised by synovitis, enthesitis, dactylitis and spondylitis usually manifesting as skin and nail psoriasis. Our understanding about the PsA disease state, its genetics, pathophysiology and comorbidities, as well as the ability to assess and treat the disease, has advanced as a result of significant collaborative efforts by rheumatologists and dermatologists in the development of classification criteria, outcome measures to assess the various clinical domains, and treatment trials with agents also used for diseases such as rheumatoid arthritis (RA) and psoriasis. Biological agents, especially the antitumour necrosis factors, have demonstrated significant efficacy and reasonable safety in all clinical domains of the disease, resulting in amelioration of clinical symptoms, inhibition of structural damage and improvement of function and quality of life. Although there is considerable overlap with RA, there are some differences in pathophysiology and approach to assessment and management that are important to consider. This paper reviews these subjects, with an emphasis on recent data.

Statistics from


  • Competing interests The author receives research grants, consultant fees and speaker honoraria from Abbott, Amgen, BiogenIDEC, Bristol-Myers Squibb, Centocor, Genentech, Pfizer, Lilly, Roche and UCB. The author also receives research grants and consultant fees from Celgene and Novartis.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.